Chad Kolean Biography and Net Worth

CFO of Cellectar Biosciences

Mr. Kolean served as Chief Financial Officer to both Vivex Biologics, a regenerative medicine company and Titan Spine, a spinal implant med-tech company sold to Medtronic. Mr. Kolean also served as Chief Financial Officer and Treasurer for Pioneer Surgical Technology, a biologic and orthopedic implant company through its merger with RTI Surgical. Early in his career, Mr. Kolean held leadership positions of increasing responsibility at multinational companies and those within the healthcare space including Tomotherapy, Inc., Metavante Corporation, Snap On, Inc., Herman Miller, Inc., Kaydon Corporation, and Arthur Andersen, LLP. Mr. Kolean earned his Bachelor of Arts in Business Administration and Finance from Hope College and graduated Magna Cum Laude.

What is Chad J. Kolean's net worth?: The estimated net worth of Chad J. Kolean is at least $11.69 thousand as of July 2nd, 2025. Mr. Kolean owns 6,418 shares of Cellectar Biosciences stock worth more than $11,694 as of October 2nd. This net worth approximation does not reflect any other assets that Mr. Kolean may own. Learn More about Chad J. Kolean's net worth.
How do I contact Chad J. Kolean?: The corporate mailing address for Mr. Kolean and other Cellectar Biosciences executives is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. Cellectar Biosciences can also be reached via phone at (608) 441-8120 and via email at [email protected]. Learn More on Chad J. Kolean's contact information.
Has Chad J. Kolean been buying or selling shares of Cellectar Biosciences?: Chad J. Kolean has not been actively trading shares of Cellectar Biosciences over the course of the past ninety days. Most recently, on Wednesday, July 2nd, Chad J. Kolean bought 5,000 shares of Cellectar Biosciences stock. The stock was acquired at an average cost of $4.99 per share, with a total value of $24,950.00. Following the completion of the transaction, the chief financial officer now directly owns 6,418 shares of the company's stock, valued at $32,025.82. Learn More on Chad J. Kolean's trading history.
Who are Cellectar Biosciences' active insiders?: Cellectar Biosciences' insider roster includes Chad Kolean (CFO), and Jarrod Longcor (COO). Learn More on Cellectar Biosciences' active insiders.
Are insiders buying or selling shares of Cellectar Biosciences?: In the last twelve months, Cellectar Biosciences insiders bought shares 2 times. They purchased a total of 17,360 shares worth more than $49,996.80. In the last twelve months, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 198 shares worth more than $732.60. The most recent insider tranaction occured on May, 7th when COO Jarrod Longcor bought 8,680 shares worth more than $24,998.40. Insiders at Cellectar Biosciences own 2.6% of the company. Learn More about insider trades at Cellectar Biosciences.
Information on this page was last updated on 5/7/2026.

Chad J. Kolean Insider Trading History at Cellectar Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/2/2025	Buy	5,000	$4.99	$24,950.00	6,418

Chad J. Kolean Buying and Selling Activity at Cellectar Biosciences

Cellectar Biosciences Company Overview

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Today's Range

Now: $1.80

$1.79

$1.98

50 Day Range

MA: $2.40

$1.80

$2.66

2 Week Range

Now: $1.80

$1.79

$6.52

Volume

43,074 shs

Average Volume

387,800 shs

Market Capitalization

$16.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58